Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2011 1
2012 1
2014 5
2015 1
2016 2
2017 2
2018 1
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Lactic Acidosis (Nursing).
Foucher CD, Tubben RE, Bryan-Irving S. Foucher CD, et al. Among authors: bryan irving s. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33760506 Free Books & Documents.
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, Pete Yeung V, Rennerfeldt DA, Henkensiefken A, Fox M, Lam S, Morrissey KM, Lange Z, Podust VN, Derynck MK, Irving BA, Schellenberger V. Cattaruzza F, et al. Among authors: irving ba. Nat Cancer. 2023 Apr;4(4):485-501. doi: 10.1038/s43018-023-00536-9. Epub 2023 Mar 30. Nat Cancer. 2023. PMID: 36997747 Free PMC article.
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, Yu W, Koditek D, Winter MB, Moore SJ, Mei L, Diep L, Huang Y, Liu S, Vasiljeva O, West J, Richardson J, Irving B, Belvin M, Kavanaugh WM. Boustany LM, et al. Among authors: irving b. Cancer Res. 2022 Nov 15;82(22):4288-4298. doi: 10.1158/0008-5472.CAN-21-2483. Cancer Res. 2022. PMID: 36112781 Free PMC article.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Among authors: irving b. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485 Free PMC article.
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, Kavanaugh WM, Vasiljeva O, Belvin M, Howng B, Irving B, Tipton K, West J, Mei L, Korman AJ, Sega E, Olivera I, Cirella A, Ochoa MC, Rodriguez ME, Melero A, Sanmamed MF, Engelhardt JJ, Melero I. Etxeberria I, et al. Among authors: irving b. Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):e2025930118. doi: 10.1073/pnas.2025930118. Proc Natl Acad Sci U S A. 2021. PMID: 34172583 Free PMC article.
Role of PD-1 during effector CD8 T cell differentiation.
Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R. Ahn E, et al. Among authors: irving ba. Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13. Proc Natl Acad Sci U S A. 2018. PMID: 29654146 Free PMC article.
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. Adusumilli PS, et al. Among authors: irving ba. J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28649381 Free PMC article. Review.
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, Chiu H, Hong R, Grogan J, Javinal V, Yauch R, Irving B, Belvin M, Mellman I, Kim JM, Schmidt M. Lau J, et al. Among authors: irving b. Nat Commun. 2017 Feb 21;8:14572. doi: 10.1038/ncomms14572. Nat Commun. 2017. PMID: 28220772 Free PMC article.
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Gunderson AJ, et al. Among authors: irving b. Cancer Discov. 2016 Mar;6(3):270-85. doi: 10.1158/2159-8290.CD-15-0827. Epub 2015 Dec 29. Cancer Discov. 2016. PMID: 26715645 Free PMC article.
18 results